Jay Venkatesan - Jul 15, 2022 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC. (ALPN)

Role: Director, 10%+ Owner
Signature: /s/ James Paul Rickey, attorney-in-fact
Stock symbol: ALPN
Transactions as of: Jul 15, 2022
Transactions value $: $0
Form type: 4
Date filed: 7/19/2022, 04:38 PM
Previous filing: May 27, 2022
Next filing: Dec 29, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALPN	Common Stock	Options Exercise	$9.03K	+20.1K	+9.2%	$0.45^*	238K	Jul 15, 2022	Direct
holding	ALPN	Common Stock						18.6K	Jul 15, 2022	By Raj Venkatesan as UTMA custodian for Reid Coleman Venkatesan	F1, F2
holding	ALPN	Common Stock						2.6M	Jul 15, 2022	By Alpine ImmunoSciences, L.P.	F1, F3
holding	ALPN	Common Stock						18.6K	Jul 15, 2022	By Raj Venkatesan as UTMA custodian for Nathaniel Graham Venkatesan	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALPN	Stock Option (Right to buy)	Options Exercise	-$9.03K	-20.1K	-22.28%	$0.45^*	70K	Jul 15, 2022	Common Stock	20.1K	$0.45	Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2	These shares are held by Raj Venkatesan as custodian for Reporting Person's sons under the California Uniform Transfers to Minors Act.
F3	Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Venkatesan is a Managing Partner of Alpine BioVenture GP, LLC. Dr. Venkatesan is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares.
F4	Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio.
F5	The Reporting Person was initially granted an option to acquire 300,000 shares, 75,000 shares of which vested on May 25, 2016, and the remaining shares vested or vest in 36 substantially equal monthly installments starting on September 1, 2016, subject to the Reporting person's continued service with the Issuer and certain change of control provisions.